Drs Whitman and Patel discuss the evolving treatment paradigm for patients with CSCC, emphasizing the role of neoadjuvant and adjuvant immunotherapies.
Eric Whitman, MD
Advertisement
Eric Whitman, MD, medical director, oncology service line, Atlantic Health System
Articles by Eric Whitman, MD
Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses ways to expand the benefit of immunotherapy in non-immunogenic solid tumors.
Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses eliminating financial toxicity in oncology.
Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses improving precision medicine in oncology.
Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses the partnership between Atlantic Health System, Translational Genomics Research Institute (TGen), and Origin Commercial Ventures.
Eric Whitman, MD, surgeon, Atlantic Health System, discusses the role of pembrolizumab (Keytruda) in the treatment of patients with melanoma.
Advertisement
Latest Updated Articles
Dr. Whitman on the Role of Pembrolizumab in MelanomaPublished: March 15th 2018 | Updated:
Dr. Whitman on the Partnership Between Atlantic Health System, TGen and OriginPublished: October 5th 2018 | Updated:
Dr. Whitman on Improving Precision Medicine in OncologyPublished: October 10th 2018 | Updated:
Dr. Whitman on Eliminating Financial Toxicity in OncologyPublished: October 17th 2018 | Updated:
Dr. Whitman on Expanding the Benefit of Immunotherapy in Solid TumorsPublished: May 17th 2019 | Updated:
Multidisciplinary Teams Optimize Surgical and Therapeutic Roles in Advanced CSCC Care: With Eric Whitman, MD; and Vishal Patel, MD, FAAD, FACMSPublished: January 31st 2026 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5